Lilly has announced promising data from its NCT 04881760 phase 2 study of retatrutide, a potential obesity drug. The drug candidate, a single peptide with agonist activity at the glucose-dependent insulinotropic polypeptide (GIP), GLP-1 and glucagon receptors, was associated with significant weight loss, improved glycemic control and cardiovascular health.
At 24 weeks, retatrutide (1 mg, 4 mg, 8 mg or 12 mg) met the primary endpoint for efficacy in participants with obesity or overweight without diabetes. Participants had a mean weight reduction of up to 17.5% (41.2 lb) at 24 weeks. That figure increased to 24.2% at 48 weeks.
The double-blind, randomized, placebo-controlled study enrolled 338 adults with obesity or overweight and related health conditions to assess the drug’s efficacy, side effects, and safety. Data from that study were published in NEJM.
Lancet recently published data from the separate phase 2 NCT04867785 study on retatrutide, in…